Orbis Biosciences, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Orbis Biosciences, Inc. – Product Pipeline Review – 2016’, provides an overview of the Orbis Biosciences, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Orbis Biosciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Orbis Biosciences, Inc.

The report provides overview of Orbis Biosciences, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Orbis Biosciences, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Orbis Biosciences, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Orbis Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Orbis Biosciences, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orbis Biosciences, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Orbis Biosciences, Inc. Snapshot 5

Orbis Biosciences, Inc. Overview 5

Key Information 5

Key Facts 5

Orbis Biosciences, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Orbis Biosciences, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Orbis Biosciences, Inc. - Pipeline Products Glance 11

Orbis Biosciences, Inc. - Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Orbis Biosciences, Inc. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Orbis Biosciences, Inc. - Drug Profiles 13

prednisone 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

betamethasone valerate ER 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

bupivacaine hydrochloride ER 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

etonogestrel ER 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

guaifenesin ER 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

meloxicam ER 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

ORB-105 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

ORB-203 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ritonavir 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

tramadol hydrochloride ER 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Orbis Biosciences, Inc. - Pipeline Analysis 23

Orbis Biosciences, Inc. - Pipeline Products by Target 23

Orbis Biosciences, Inc. - Pipeline Products by Route of Administration 24

Orbis Biosciences, Inc. - Pipeline Products by Molecule Type 25

Orbis Biosciences, Inc. - Pipeline Products by Mechanism of Action 26

Orbis Biosciences, Inc. - Locations And Subsidiaries 27

Head Office 27

Appendix 28

Methodology 28

Coverage 28

Secondary Research 28

Primary Research 28

Expert Panel Validation 28

Contact Us 28

Disclaimer 29

List of Tables

List of Tables

Orbis Biosciences, Inc., Key Information 5

Orbis Biosciences, Inc., Key Facts 5

Orbis Biosciences, Inc. – Pipeline by Indication, 2016 7

Orbis Biosciences, Inc. – Pipeline by Stage of Development, 2016 9

Orbis Biosciences, Inc. – Monotherapy Products in Pipeline, 2016 10

Orbis Biosciences, Inc. – Phase I, 2016 11

Orbis Biosciences, Inc. – Preclinical, 2016 12

Orbis Biosciences, Inc. – Pipeline by Target, 2016 23

Orbis Biosciences, Inc. – Pipeline by Route of Administration, 2016 24

Orbis Biosciences, Inc. – Pipeline by Molecule Type, 2016 25

Orbis Biosciences, Inc. – Pipeline Products by Mechanism of Action, 2016 26

List of Figures

List of Figures

Orbis Biosciences, Inc. – Pipeline by Top 10 Indication, 2016 7

Orbis Biosciences, Inc. – Pipeline by Stage of Development, 2016 9

Orbis Biosciences, Inc. – Monotherapy Products in Pipeline, 2016 10

Orbis Biosciences, Inc. – Pipeline by Top 10 Target, 2016 23

Orbis Biosciences, Inc. – Pipeline by Route of Administration, 2016 24

Orbis Biosciences, Inc. – Pipeline by Molecule Type, 2016 25

Orbis Biosciences, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 26

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports